Needham & Company LLC reissued their buy rating on shares of NeoGenomics (NASDAQ:NEO - Free Report) in a report issued on Friday morning,Benzinga reports. They currently have a $19.00 target price on the medical research company's stock.
Other analysts have also issued research reports about the company. Benchmark reissued a "buy" rating and set a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th. Jefferies Financial Group began coverage on NeoGenomics in a research report on Tuesday, December 10th. They set a "buy" rating and a $22.00 price target on the stock. Finally, Bank of America raised their target price on shares of NeoGenomics from $18.00 to $19.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.30.
Check Out Our Latest Stock Analysis on NeoGenomics
NeoGenomics Stock Down 20.6 %
Shares of NeoGenomics stock traded down $3.84 on Friday, hitting $14.77. The company had a trading volume of 2,547,607 shares, compared to its average volume of 950,200. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -24.21 and a beta of 1.24. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. NeoGenomics has a 1 year low of $12.77 and a 1 year high of $19.11. The stock has a 50 day moving average of $16.81 and a 200-day moving average of $15.63.
NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.04. The company had revenue of $167.80 million for the quarter, compared to analysts' expectations of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. NeoGenomics's revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.06) EPS. As a group, sell-side analysts forecast that NeoGenomics will post -0.16 earnings per share for the current year.
Insider Activity
In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares in the company, valued at approximately $570,301.44. This trade represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.30% of the company's stock.
Hedge Funds Weigh In On NeoGenomics
Institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc boosted its position in NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after purchasing an additional 1,142 shares in the last quarter. Quarry LP purchased a new stake in shares of NeoGenomics in the third quarter valued at approximately $40,000. Blue Trust Inc. increased its stake in shares of NeoGenomics by 42.3% in the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company's stock worth $46,000 after acquiring an additional 987 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in NeoGenomics during the second quarter worth about $57,000. Finally, KBC Group NV raised its position in shares of NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock valued at $67,000 after buying an additional 1,127 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Read More
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
